Image

Mississauga, Ontario Study Details

Study Reference No. - C1D06019/6020

Study Reference No. Study Type Compensation Gender Age Demographic
C1D06019/6020 Healthy $2,970 Males & Females 18 to 55 In good health, non-smokers for at least the past one year
Study Details

Study Purpose

The purpose of this study is to compare how much active drug is present in your blood after taking a 40 mg dose of Rifaximin from each of the 3 test study product tablets under fasting and fed conditions.

Study Duration

Study duration is approximately 18 days from first period dosing until the last blood sample collection of the study in the final period; 3 periods, each spaced at least 6 days apart; confinement is for approximately 34 hrs. for each period (from check-in until about 24 hours after dosing (2 overnight stays); 2 ambulatory visits per period at 36 and 48 hours.

Study Schedule

General Screening

NA

Medical Screening

October 2, 6, 9, 16

Study Visit(s)
Period 1 Period 2 Period 3
Check-in (PM) 22-Oct-25 29-Oct-25 05-Nov-25
Dosing (AM) 23-Oct-25 30-Oct-25 06-Nov-25
Check-out (AM) 24-Oct-25 31-Oct-25 07-Nov-25
Return Visit Period 1 Period 2 Period 3
36 hours(PM) 24-Oct-25 31-Oct-25 07-Nov-25
48 hours(AM) 25-Oct-25 01-Nov-25 08-Nov-25

Follow-Up Visit(s)

See study visit schedule.

Other Notes

Bring Valid Photo ID.
I'm Interested!